Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pretomanid in Children With Rifampicin-Resistant Tuberculosis
NCT05586230Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2023
- Primary completion
- Apr 2026
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of pretomanid in Tuberculosis (TB) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Area Under the Curve from Time Zero to Infinity at 48 hours, Apparent Oral Clearance at 48 hours and 4 more. Started Oct 2023; status: completed.
02
Drugs
pretomanid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05586230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05586230.